Overview

Purevax RC is a veterinary vaccine used to protect cats from the age of 8 weeks against feline viral rhinotracheitis (a flu-like illness caused by a herpesvirus) and feline calicivirosis (a flu-like illness with inflammation of the mouth caused by a calicivirus). The vaccine helps to reduce the symptoms of the diseases.

Purevax RC contains attenuated (weakened) feline rhinotracheitis herpesvirus (FHV F2 strain) and inactivated (killed) calicivirosis antigens (FCV 431 and G1 strains) as active substance.

Purevax RC is available as a lyophilisate (freeze-dried pellet) and solvent that are made up into a suspension for injection. The vaccine is given as two doses injected under the skin. The first injection should be given in kittens aged at least eight weeks, with a second injection three to four weeks later. If the kitten has high levels of antibodies received from the mother in the womb and in the milk, the first vaccination should be delayed until 12 weeks of age. The cat should be revaccinated for all components one year after the first vaccination course, then every three years.

For more information about using Purevax RC, see the package leaflet or contact your veterinarian or pharmacist.

Purevax RC is a vaccine. Vaccines work by ‘teaching’ the immune system (the body’s natural defences) how to defend itself against a disease. Purevax RC contains small amounts of weakened or killed viruses that cause feline rhinotracheitis and calicivirosis.

When a cat is given the vaccine, the immune system recognises the weakened or killed viruses as ‘foreign’ and makes antibodies against them. In the future, the immune system will be able to produce antibodies more quickly when it is again exposed to the viruses. The antibodies will help to protect against the diseases caused by these viruses. When exposed to any of these viruses later in life, the cat will either not become infected or have a much less serious infection.

The effectiveness of Purevax RC has been studied in several trials in laboratory conditions where cats were vaccinated and infected with herpesvirus and calicivirus. In the field, the studies of Purevax RC looked at the basic vaccination schedule (2 injections 3–4 weeks apart) and at the booster vaccination. They included young and adult cats of various breeds, but not young kittens. The main measure of effectiveness was the level of antibodies in the blood against the viruses in the vaccine.

In laboratory conditions Purevax RC was demonstrated to provide protection against the diseases listed above. In the field study of basic vaccination there was an increase in antibodies against feline rhinotracheitis herpesvirus and calicivirus infection. In the study looking at booster vaccination, antibody levels against rhinotracheitis herpesvirus and calicivirus infection remained stable at a high level or increased slightly.

The most common side effects with Purevax RC (which may affect up to 1 in 10 animals) are temporary apathy (loss of interest in surroundings) and anorexia (loss of appetite), as well as hyperthermia (elevated body temperature) lasting for one or two days. There may be a local reaction at the injection site, with slight pain on touching, itching or oedema (swelling), which disappears within one or two weeks.

Purevax RC should not be used in pregnant cats and during lactation.

For the full list of side effects and restrictions of Purevax RC, see the package leaflet.

In case of accidental self-injection medical advice should be sought immediately and the package leaflet or the label shown to the doctor.

The European Medicines Agency decided that Purevax RC’s benefits are greater than its risks and it can be authorised for use in the EU. 

Purevax RC received a marketing authorisation valid throughout the EU on 23 February 2005. 

български (BG) (155.13 KB - PDF)

View

español (ES) (141.77 KB - PDF)

View

čeština (CS) (168.53 KB - PDF)

View

dansk (DA) (141.9 KB - PDF)

View

Deutsch (DE) (146.4 KB - PDF)

View

eesti keel (ET) (139.71 KB - PDF)

View

ελληνικά (EL) (154.46 KB - PDF)

View

français (FR) (142.99 KB - PDF)

View

hrvatski (HR) (162.43 KB - PDF)

View

italiano (IT) (139.22 KB - PDF)

View

latviešu valoda (LV) (169.1 KB - PDF)

View

lietuvių kalba (LT) (163.25 KB - PDF)

View

magyar (HU) (172.94 KB - PDF)

View

Malti (MT) (170.28 KB - PDF)

View

Nederlands (NL) (142.71 KB - PDF)

View

polski (PL) (164.65 KB - PDF)

View

português (PT) (142.26 KB - PDF)

View

română (RO) (169.48 KB - PDF)

View

slovenčina (SK) (162.5 KB - PDF)

View

slovenščina (SL) (159.34 KB - PDF)

View

Suomi (FI) (139.31 KB - PDF)

View

svenska (SV) (140.66 KB - PDF)

View

Product information

български (BG) (211.54 KB - PDF)

View

español (ES) (101.8 KB - PDF)

View

čeština (CS) (193.1 KB - PDF)

View

dansk (DA) (114.07 KB - PDF)

View

Deutsch (DE) (101.61 KB - PDF)

View

eesti keel (ET) (131.56 KB - PDF)

View

ελληνικά (EL) (215.04 KB - PDF)

View

français (FR) (104.12 KB - PDF)

View

hrvatski (HR) (190.31 KB - PDF)

View

íslenska (IS) (120.52 KB - PDF)

View

italiano (IT) (105.72 KB - PDF)

View

latviešu valoda (LV) (193.36 KB - PDF)

View

lietuvių kalba (LT) (200.45 KB - PDF)

View

magyar (HU) (187.63 KB - PDF)

View

Malti (MT) (211.97 KB - PDF)

View

Nederlands (NL) (98.64 KB - PDF)

View

norsk (NO) (97.98 KB - PDF)

View

polski (PL) (200.88 KB - PDF)

View

português (PT) (111.34 KB - PDF)

View

română (RO) (200.02 KB - PDF)

View

slovenčina (SK) (197.58 KB - PDF)

View

slovenščina (SL) (181.55 KB - PDF)

View

Suomi (FI) (104.37 KB - PDF)

View

svenska (SV) (103.52 KB - PDF)

View

Latest procedure affecting product information: WS2201/0027

17/02/2022

български (BG) (78.36 KB - PDF)

View

español (ES) (59.67 KB - PDF)

View

čeština (CS) (74.1 KB - PDF)

View

dansk (DA) (59.82 KB - PDF)

View

Deutsch (DE) (53.33 KB - PDF)

View

eesti keel (ET) (51.13 KB - PDF)

View

ελληνικά (EL) (70.88 KB - PDF)

View

français (FR) (36.93 KB - PDF)

View

hrvatski (HR) (69.59 KB - PDF)

View

íslenska (IS) (59.1 KB - PDF)

View

italiano (IT) (43.4 KB - PDF)

View

latviešu valoda (LV) (74.55 KB - PDF)

View

lietuvių kalba (LT) (73.56 KB - PDF)

View

magyar (HU) (67.08 KB - PDF)

View

Malti (MT) (68.11 KB - PDF)

View

Nederlands (NL) (54.06 KB - PDF)

View

norsk (NO) (42.53 KB - PDF)

View

polski (PL) (69 KB - PDF)

View

português (PT) (55.39 KB - PDF)

View

română (RO) (66.83 KB - PDF)

View

slovenčina (SK) (69.79 KB - PDF)

View

slovenščina (SL) (68 KB - PDF)

View

Suomi (FI) (36.07 KB - PDF)

View

svenska (SV) (53.32 KB - PDF)

View

Product details

Name of medicine
Purevax RC
Active substance
  • attenuated feline rhinotracheitis herpesvirus (FHV F2 strain)
  • inactivated feline calicivirosis antigens (FCV 431 and G1 strains)
International non-proprietary name (INN) or common name
vaccine against feline viral rhinotracheitis and feline calicivirosis
Species
Cats
Anatomical therapeutic chemical veterinary (ATCvet) code
QI06AH08

Pharmacotherapeutic group

Immunologicals for felidae

Therapeutic indication

Active immunisation of cats aged eight weeks and older:

  • against feline viral rhinotracheitis to reduce clinical signs;
  • against calicivirus infection to reduce clinical signs.

Onsets of immunity isone week after primary vaccination course.

The duration of immunity is one year after primary vaccination course and three years after the last re-vaccination.

Authorisation details

EMA product number
EMEA/V/C/000091
Marketing authorisation holder
Boehringer Ingelheim Vetmedica GmbH

55216 Ingelheim am Rhein
Germany

Opinion adopted
10/11/2004
Marketing authorisation issued
23/02/2005
Revision
16

Assessment history

News on Purevax RC

Topics

This page was last updated on

How useful do you find this page?